PENILE CANCER
Clinical trials for PENILE CANCER explained in plain language.
Never miss a new study
Get alerted when new PENILE CANCER trials appear
Sign up with your email to follow new studies for PENILE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double antibody attack: early trial combines immune and Growth-Signal blockers against advanced cancers
Disease control CompletedThis early-stage trial is testing a combination of two lab-made antibodies in people with advanced solid tumors that have not responded to standard treatments. One antibody (LDP) aims to reactivate the immune system against cancer, while the other (CDP1) blocks a growth signal on…
Matched conditions: PENILE CANCER
Phase: PHASE1 • Sponsor: Dragonboat Biopharmaceutical Company Limited • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
Disease control CompletedThis study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…
Matched conditions: PENILE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take on HPV cancers
Disease control CompletedThis trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…
Matched conditions: PENILE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
Diagnosis CompletedThis trial tests whether a new hybrid tracer, ICG-99mTc-nanoscan, can replace the standard tracer for sentinel node biopsy in people with penile cancer, melanoma, or oral cancer. The hybrid tracer combines a fluorescent dye with a radioactive marker, potentially allowing surgeons…
Matched conditions: PENILE CANCER
Phase: NA • Sponsor: The Netherlands Cancer Institute • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC